English
Home > Products > 755037-03-7

China 755037-03-7 Factory

We continuously execute our spirit of ''Innovation bringing development, Highly-quality ensuring subsistence, Management advertising and marketing gain, Credit history attracting buyers for 755037-03-7,CAS NO 755037-03-7,Regorafenib API,Regorafenib, Our business has already setup a professional, creative and responsible workforce to develop purchasers together with the multi-win principle.
755037-03-7, we sincerely hope to establish a good and long-term business relationship with your esteemed company through this opportunity, based on equality, mutual benefit and win-win business from now to the future. "Your satisfaction is our happiness".

Related Products

Hot Products

  • ethyl-2,2-dimethyl-7-bromoheptanoate

    ethyl-2,2-dimethyl-7-bromoheptanoate

    Product Name:ethyl-2,2-dimethyl-7-bromoheptanoate
    Molecular Formula:C11H21BrO2
    Molecular Weight:265.19
    CAS Registry Number:123469-92-1
  • SODIUM 2,6-DIFLUOROBENZOATE

    SODIUM 2,6-DIFLUOROBENZOATE

    Product Name:SODIUM 2,6-DIFLUOROBENZOATE
    Molecular Formula:C7H3F2NaO2
    Molecular Weight:180.0840964
    CAS Registry Number:6185-28-0
  • Nebivolol hydrochloride

    Nebivolol hydrochloride

    Product Name:Nebivolol hydrochloride
    Molecular Formula:C22H26ClF2NO4
    Molecular Weight;441.9
    CAS Registry Number;152520-56-4
  • Dapagliflozin propanediol monohydrate

    Dapagliflozin propanediol monohydrate

    Product Name:Dapagliflozin propanediol monohydrate
    Molecular Formula:C24H33ClO8
    Molecular Weight:484.97
    CAS Registry Number:960404-48-2
  • Atosiban Acetate

    Atosiban Acetate

    Product Name:Atosiban Acetate
    Molecular Formula:C45H71N11O14S2
    Molecular Weight;1054.25
    CAS Registry Number;914453-95-5
  • Filgotinib maleate

    Filgotinib maleate

    Product Name:Filgotinib maleate
    Molecular Formula:C25H27N5O7S
    Molecular Weight;541.58
    CAS Registry Number;1802998-75-9
  • Related Blog
  • Reviews

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 755037-03-7

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept